We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Notification of Date of Preliminary Results and Update on Stroke Clinical Trial
Product News

Notification of Date of Preliminary Results and Update on Stroke Clinical Trial

Notification of Date of Preliminary Results and Update on Stroke Clinical Trial
Product News

Notification of Date of Preliminary Results and Update on Stroke Clinical Trial


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Notification of Date of Preliminary Results and Update on Stroke Clinical Trial"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ReNeuron Group plc has announced the completion of dosing of the first cohort of patients in the PISCES clinical trial of its ReN001 stem cell therapy for disabled stroke patients.

The PISCES study (Pilot Investigation of Stem Cells in Stroke) is the world’s first fully regulated clinical trial of a neural stem cell therapy for disabled stroke patients.

The PISCES clinical trial is being conducted in Scotland at the Institute of Neurological Sciences, Southern General Hospital, Greater Glasgow and Clyde NHS Board.

In line with the update given in March, the last of the three patients in this dose cohort was treated with ReN001 earlier this month and was safely discharged from hospital two days later.

In this Phase I single administration dose escalation study, ReNeuron’s ReN001 stem cell therapy is being administered to a total of 12 stroke patients who have been left disabled by an ischaemic stroke, the most common form of the condition.

The aim of the study is to test the safety and tolerability of the treatment in progressive doses whilst assessing longer term efficacy measures for the design of future clinical trials with ReN001.

The Company will provide a further update on the PISCES clinical trial in its 2011 preliminary results statement. The Group will report its preliminary results for the year ended 31 March 2011 on Thursday 30 June 2011.

A briefing for analysts will be held at 10:00am (BST) on the day at the offices of Buchanan Communications, 107 Cheapside, London EC2V 5DN.

Advertisement